Drug Profile


Alternative Names: BIIB-019; DAC HYP; Dacliximab; Daclizumab high-yield process; Daclizumab HYP; HAT antibody; Humanised anti-Tac antibody; R35; RO 247375; SMART anti-Tac antibody; Zenapax; Zinbryta

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Biogen; Dana-Farber Cancer Institute; National Cancer Institute (USA); PDL BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis; Renal transplant rejection
  • Discontinued Asthma; Graft-versus-host disease; Haematological malignancies; Immune-mediated uveitis; Liver transplant rejection; Psoriasis; Tropical spastic paraparesis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 13 Mar 2017 Biogen and AbbVie initiate enrolment in the phase IIIb SUSTAIN trial for Multiple sclerosis in the United Kingdom (EudraCT2016-002820-10)
  • 09 Dec 2016 Registered for Multiple sclerosis (Recurrent) in Canada (SC)
  • 15 Sep 2016 Interim efficacy data from the phase III trial in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top